Online citations, reference lists, and bibliographies.
← Back to Search

6-Mercaptopurine And Daunorubicin Double Drug Liposomes—Preparation, Drug-Drug Interaction And Characterization

Vineet Agrawal, Manash K. Paul, A. Mukhopadhyay
Published 2005 · Medicine, Chemistry

Cite This
Download PDF
Analyze on Scholarcy
Share
This article addresses and investigates the dual incorporation of daunorubicin (DR) and 6-mercaptopurine (6-MP) in liposomes for better chemotherapy. These drugs are potential candidates for interaction due to the quinone (H acceptor) and hydroxyl (H donor) groups on DR and 6-MP, respectively. Interactions between the two drugs in solution were monitored by UV/Vis and fluorescence spectroscopy. Interaction between the two drugs inside the liposomes was evaluated by HPLC (for 6-MP) and by fluorescence spectroscopy (for daunorubicin) after phospholipase-mediated liposome lysis. Our results provide evidence for the lack of interaction between the two drugs in solution and in liposomes. The entrapment efficiencies of 6-MP in the neutral Phosphatidyl choline (PC):Cholesterol (Chol):: 2:1 and anionic PC:Chol:Cardiolipin (CL) :: 4:5:1 single and double drug liposomes were found to be 0.4% and 1.5% (on average), respectively. The entrapment efficiencies of DR in the neutral and anionic double drug liposomes were found to be 55% and 31%, respectively. The corresponding entrapment of daunorubicin in the single drug liposomes was found to be 62% on average. Our thin layer chromatography (TLC) and transmission electron microscopy (TEM) results suggest stability of lipid and liposomes, thus pointing plausible existence of double drug liposomes. Cytotoxicity experiments were performed by using both single drug and double drug liposomes. By comparing the results of phase contrast and fluorescence microscopy, it was observed that the double drug liposomes were internalized in the jurkat and Hut78 (highly resistant cell line) leukemia cells as viewed by the fluorescence of daunorubicin. The cytotoxicity was dose dependent and had shown a synergistic effect when double drug liposome was used.
This paper references
Freifelder, D, ed
D. Freifelder (1982)
A novel cancer therapy based on oxygen radicals.
T. Yoshikawa (1995)
10.1001/ARCHINTE.1966.00290180091025
The Pharmacological Basis of Therapeutics.
E. D. Cyan (1966)
Liposome Technology
L. D. Mayer (1993)
10.1073/PNAS.78.3.1873
Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.
E. Forssen (1981)
Tumor-targeting chemotherapy by a xanthine oxidase-polymer conjugate that generates oxygen-free radicals in tumor tissue.
T. Sawa (2000)
10.1016/S1368-7646(03)00082-7
Liposome-based approaches to overcome anticancer drug resistance.
C. Mamot (2003)
10.1016/J.DRUP.2004.01.004
ROS stress in cancer cells and therapeutic implications.
H. Pelicano (2004)
10.1182/BLOOD.V100.2.594
Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid.
X. Q. Pan (2002)
Multiple step entrapment / loading procedure for preparing lipophilic drug-containing liposomes
에릭 안톤포오슨 (1988)
10.1080/14733400410001727592
Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
C. Mamot (2003)
10.1016/S0378-5173(98)00006-4
Lipophilic drug derivatives in liposomes
Monica Gulati (1998)
10.1016/S0076-6879(89)71012-0
[9] Liposome preparation and size characterization
M. Woodle (1989)
10.1016/0005-2736(93)90218-O
Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients.
P. Harrigan (1993)
10.1016/S0006-2952(98)00307-4
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.
D. Gewirtz (1999)
10.1038/SCIENTIFICAMERICAN0389-44
Multidrug resistance in cancer.
N. Kartner (1989)
Delgado, J
W. A. Remers (1998)
10.1073/PNAS.93.21.11848
Reactive oxygen species are downstream mediators of p53-dependent apoptosis.
T. Johnson (1996)
10.1111/J.1432-1033.1996.00879.X
The overall partitioning of anthracyclines into phosphatidyl-containing model membranes depends neither on the drug charge nor the presence of anionic phospholipids.
L. Gallois (1996)
Liposomal protection of adriamycin-induced cardiotoxicity in mice.
A. Rahman (1980)
10.1006/BBRC.1999.0208
Activation of caspase 3 in HL-60 cells exposed to hydrogen peroxide.
A. Dipietrantonio (1999)
Liposome preparation and size characterization.
M. Woodle (1989)
10.1096/fasebj.4.13.2210154
Doxorubicin cardiotoxicity: analysis of prevailing hypotheses
R. Olson (1990)
10.3109/03639049309062967
CDP-choline entrapment and release from multilamellar and reverse-phase evaporation liposomes
M. Fresta (1993)
10.1016/S0140-6736(89)91085-4
Multidrug Resistance in Cancer
D. Ferry (1989)
Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry
J. Beale (1991)



This paper is referenced by
10.1007/978-3-319-43525-1
Intracellular Delivery III
A. Prokop (2016)
10.2174/1871520618666180420170124
Liposomes Co- encapsulating Anticancer Drugs in Synergistic Ratios as an Approach to Promote Increased Efficacy and Greater Safety.
Marina Santiago Franco (2019)
10.1016/J.JDDST.2017.07.004
Synthesis and characterization of ZIF-8 nanoparticles for controlled release of 6-mercaptopurine drug
H. Kaur (2017)
10.4155/tde.13.149
Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy.
B. Liboiron (2014)
10.1201/B18654-5
Liposomes as a Drug Delivery System
Kacoli Banerjee (2015)
10.1007/s12010-011-9383-z
Theranostic Applications of Nanomaterials in Cancer: Drug Delivery, Image-Guided Therapy, and Multifunctional Platforms
A. Fernandez-Fernandez (2011)
10.15171/ipp.2019.17
A review on application of nanoparticles for cancer therapy
Mohamad Ali Dayani (2019)
10.3109/08982100903244500
Preparation and characterization of medium-chain fatty acid liposomes by lyophilization
Chengmei Liu (2010)
10.1016/j.colsurfb.2014.09.046
Lethal drug combination: arsenic loaded multiple drug mesoporous silica for theranostic applications.
Faheem Muhammad (2014)
10.1021/mp500066v
Nanomaterial-induced autophagy: a new reversal MDR tool in cancer therapy?
E. Panzarini (2014)
10.5958/2231-5713.2015.00008.2
A Review- Emerging Use of Nano-Based Carriers in Diagnosis and Treatment of Cancer-Novel Approaches
Yaqub Khan (2015)
10.2174/1389200216666150223152958
Advances and challenges in the use of nanoparticles to optimize PK/PD interactions of combined anti-cancer therapies.
Yarong Liu (2014)
10.1016/J.JLUMIN.2008.10.020
Photophysical study on daunorubicin by fluorescence spectroscopy
M. Htun (2009)
10.1016/j.jconrel.2019.03.015
Threatening cancer with nanoparticle aided combination oncotherapy
Shruti Rawal (2019)
10.12991/jrp.2018.72
Analysis of anticancer drugs using thin layer chromatography- A review
Duygu Yeniceli Uğur (2018)
Drug Loading and Release from Functionalized Multiwalled Carbon Nanotubes Loaded With 6-Mercaptopurine Using Incipient Wetness Impregnation Method
S. Ghoshal (2014)
Trwałość [(N-pirolidyno)metyleno]daunorubicyny w roztworach wodnych
Uszak Justyna (2010)
10.1007/978-3-319-43525-1_16
Exploiting Nanocarriers for Combination Cancer Therapy
Y. W. Kong (2016)
10.3389/fimmu.2020.00945
Nanoparticle Platforms for Antigen-Specific Immune Tolerance
Edward B Thorp (2020)
10.1039/C3PY00085K
Synthesis of Nanogel-Protein Conjugates.
Nicholas M. Matsumoto (2013)
10.1016/j.jconrel.2019.01.011
Combinatorial nanocarriers against drug resistance in hematological cancers: Opportunities and emerging strategies
Saikat Ghosh (2019)
10.1016/J.TAAP.2007.09.020
Dithiothreitol abrogates the effect of arsenic trioxide on normal rat liver mitochondria and human hepatocellular carcinoma cells.
Manash K. Paul (2008)
Synergistic cytotoxic effects of arsenic trioxide plus dithiothreitol on mice oral cancer cells.
C. Tsai (2010)
10.1016/j.saa.2013.10.014
Fluorescence quenching and spectrophotometric methods for the determination of daunorubicin with meso-tera (4-sulphophenyl) porphyrin as probe.
J. Tian (2014)
10.2147/OTT.S119362
Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors
Bilal Zulfiqar (2017)
10.1021/bm501285t
Advances in combination therapies based on nanoparticles for efficacious cancer treatment: an analytical report.
S. Mignani (2015)
10.1155/2012/915375
Combination Drug Delivery Approaches in Metastatic Breast Cancer
J. H. Lee (2012)
10.1016/J.SBSR.2016.08.002
Multifunctional nanoparticle developments in cancer diagnosis and treatment
S. Parvanian (2017)
10.1039/C3TB20452A
Multifunctional Chitosan Magnetic-Graphene (CMG) Nanoparticles: a Theranostic Platform for Tumor-targeted Co-delivery of Drugs, Genes and MRI Contrast Agents.
C. Wang (2013)
Release Kinetic Profiles of 6-Mercaptopurine Loaded Covalently Functionalized Multiwalled Carbon Nanotubes
Mk Mishra (2014)
10.1016/j.ijpharm.2013.03.006
Second generation liposomal cancer therapeutics: transition from laboratory to clinic.
K. Sen (2013)
10.1039/C2JM35232J
Co-delivery of all-trans-retinoic-acid and cisplatin(IV) prodrug based on polymer–drug conjugates for enhanced efficacy and safety
Rui Wang (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar